Human Genome Sciences Names Craig C. Parker Senior Vice President, Strategy and Corporate Development

ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Craig C. Parker has joined the company as Senior Vice President, Strategy and Corporate Development. He will report directly to H. Thomas Watkins, President and Chief Executive Officer, and will serve as a member of the Management Committee of the Company.

Mr. Parker was most recently CEO and co-founder of Vega Therapeutics, Inc., a biotechnology start-up focused on inflammation, obesity and insulin resistance. He was formerly Senior Vice President of Corporate Development and Finance and Chief Financial Officer of Proteolix Inc., a venture-backed development stage biotechnology company that was acquired by Onyx Pharmaceuticals in 2009. Prior to Proteolix, he was President of DCD BioConsulting LLC, a strategic and financial advisory firm to the biotechnology industry.

“Craig Parker brings more than 20 years’ experience to HGS, with a track record of accomplishment in planning, strategic analysis and business development. We are pleased to welcome him at this important time for our company,” said Mr. Watkins. “Partnering with our commercial, finance and R&D teams, Craig will lead future development of our global business strategy as well as the evaluation and execution of business development opportunities.”

From 2002-2007, Mr. Parker served as Managing Director and head of Biotechnology Equity Research at Lehman Brothers. His earlier career included senior executive positions in strategic planning and finance, biotechnology equity research and venture capital at Sprout Group, Immunex Corporation, Donaldson, Lufkin and Jenrette, and J.P. Morgan & Co.

Mr. Parker received an AB degree in Biological Sciences from the University of Chicago and an MBA from the University of Michigan Ross School of Business, and did graduate work in Medicine and Cell Biology at the Georgetown University School of Medicine. He serves as a member of the Science Advisory Board of the Life Sciences Institute (LSI) at the University of Michigan and chairs the Institute's Leadership Council. He is also a Mentor to the LSI’s Innovation Partnership Fund, a unique initiative providing funding and expert guidance to LSI scientists pursuing discoveries with exceptional clinical and commercial potential.

ABOUT HUMAN GENOME SCIENCES

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.

For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to [email protected] or by calling HGS at (877) 822-8472.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.



CONTACT:

Human Genome Sciences, Inc.
Media:
Susannah Budington, 301-545-1062
Director, Corporate Public Relations
or
Jerry Parrott, 301-315-2777
Vice President, Corporate Communications
or
Investors:
Claudine Prowse, Ph.D., 301-315-1785
Executive Director, Investor Relations
or
Peter Vozzo, 301-251-6003
Senior Director, Investor Relations

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.